National Cancer Institute of Milan

May 26, 2020

ASCO press program highlights COVID-19 outcomes in lung cancer patients

People with thoracic cancers sickened by COVID-19 were especially vulnerable to deaths with a 35% mortality rate, according to early results from TERAVOLT, a global consortium that tracks outcomes among this vulnerable patient population.

By Tom Wilemon